Concentra Biosciences to Acquire Elevation Oncology for $0.36 Per Share Plus Contingent Value Rights
核心洞察
Concentra Biosciences (搜索) has entered into a definitive merger agreement to acquire Elevation Oncology for $0.36 in cash per share plus contingent value rights.
The contingent value rights include 100% of closing net cash exceeding $26.4 million and 80% of net proceeds from EO-1022 disposition within specified timeframes.
Elevation Oncology's Board of Directors unanimously approved the acquisition, with the tender offer expected to commence by June 23, 2025 and transaction closure anticipated in July 2025.
Concentra Biosciences (搜索), LLC has entered into a definitive merger agreement to acquire Elevation Oncology, Inc. (Nasdaq: ELEV) for $0.36 in cash per share of common stock plus one non-tradeable contingent value right (CVR). The acquisition was announced on June 9, 2025, marking a significant consolidation move in the oncology sector.
Transaction Structure and Terms
The contingent value rights provide shareholders with additional potential value through two mechanisms: 100% of the closing net cash in excess of $26.4 million, and 80% of any net proceeds received within five years following closing from any disposition of EO-1022 that occurs within one year following closing. These provisions are outlined in the contingent value rights agreement accompanying the merger.
The Elevation Oncology Board of Directors has unanimously determined that the acquisition by Concentra is in the best interests of all stockholders and has approved the merger agreement and related transactions.
Tender Offer Process
A wholly owned subsidiary of Concentra will commence a tender offer by June 23, 2025 to acquire all outstanding shares of common stock. The closing of the offer is subject to several conditions, including the tender of common stock representing at least a majority of the total number of outstanding shares, the availability of at least $26.4 million of cash net of transaction costs and other liabilities at closing, and other customary closing conditions.
Elevation Oncology officers, directors and their respective affiliates holding approximately 5.1% of common stock have signed tender and support agreements under which such parties have agreed to tender their shares in the offer and support the merger transaction. The merger transaction is expected to close in July 2025.
Company Background
Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer (搜索) therapies to treat patients across a range of solid tumors (搜索) with significant unmet medical needs. The company's pipeline includes EO-1022, which features prominently in the contingent value rights structure of the acquisition deal.
Legal Representation
Fenwick & West LLP is acting as legal counsel to Elevation Oncology, while Gibson, Dunn & Crutcher LLP is acting as legal counsel to Concentra Biosciences (搜索) in this transaction.